Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment for HER-2/neu Status in Taiwanese Breast Cancer Patients

Kuo, Shou‐Jen; Wang, Boris Bao-Tyan; Chang, Cheng-Shyong; Chen, Tze-Ho; Yeh, Kun-Tu; Lee, Dong Hoon; Yin, Pao-Lun; Chen, Ming

doi:10.1016/s1028-4559(07)60008-4

Cited by 18 publications

(19 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene amplification could be demonstrated only in some of the samples that are found 2+ by IHC (Yeh). Studies have reported that FISH positivity in IHC 2+ samples varies between 7% and 89% (Ciampa et al, 2006;Rossi et al, 2006;Kuo et al, 2007;Sui et al, 2009;Goud et al, 2012;Zhang et al, 2012). Such diverse results might be due to the differences in the number of patients included in studies, centers' and/or pathologists' experience, and the test kits used.…”

Section: Discussionmentioning

confidence: 99%

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

Sağlıcan¹,

İnce²

2015

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY: HER2 amplification or overexpression is considered as disease outcome and a predictive marker of response to treatment in breast cancer. The present study aimed to compare the results of IHC and FISH for determining HER2 and to search the interpretational differences. Samples (n= 169), of which 31 were the paraffin blocks sent from outer centers, that underwent FISH analysis for HER-2 were included. Samples were re-reviewed by IHC in our laboratory. FISH test was negative in 131 (77.5%) and positive in 38 (22.5%). When those with previous IHC 0-1+ were re-reviewed, the results were found again 0-1+ and none of them was FISH positive. Inconsistency between re-reviewed IHC and previous IHC results was 25% for those with 2+ score and 11% for those with 3+ score. Consistency between IHC and FISH was 17% and 67% for previous IHC 2+ and 3+, respectively, whereas it was 23% and %75 for re-reviewed IHC 2+ and 3+, respectively. Whilst 79% of the samples evaluated as 2+ by the inexperienced pathologist were found to be 0-1+ on the re-review, all of them were FISH negative. According to our results, we suggest that samples with IHC 2+ should be re-reviewed by consulting with an experienced pathologist.

show abstract

Section: Discussionmentioning

confidence: 99%

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

Sağlıcan¹,

İnce²

2015

Int. J. Morphol.

View full text Add to dashboard Cite

show abstract

“…Comparative studies have confirmed a high concordance rate in breast carcinomas with IHC score 3? or 1?/0 between these two techniques [6,7]. However, discrepancies in the published literature regarding the equivocal cases (IHC 2?)…”

Section: Discussionmentioning

confidence: 99%

“…or 1? cases [6,7]. However, variable findings with a high rate of falsepositive results were observed by follow-up negative FISH in equivocal IHC 2?…”

Section: Introductionmentioning

confidence: 99%

HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases

Zhang

Ren

Wang

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

The concordance rate between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) on evaluating HER-2/neu status is still controversial, especially for the IHC 2+/equivocal cases. In this study, we investigated the amplification of HER-2/neu gene by FISH in IHC (2+)/equivocal specimens to clarify the correlation between HER-2/neu and clinicopathologic features of breast cancers. HER-2/neu amplification was determined by FISH on 528 specimens of breast carcinomas with equivocal expression of HER-2/neu protein by IHC detection. 65.5 % of IHC 2+ patients were negative for HER-2/neu amplification, 29.0 % were positive and the remaining was equivocal. A statistically significant inverse association was found between hormone receptor expression and HER-2/neu amplification (P < 0.05). Furthermore, polysomy of CEP17 was detected in 60 % of breast carcinomas. The results highlight the necessity of FISH test for further categorization when breast carcinoma cases are scored 2+ by IHC.

show abstract

“…Countries with the same level of resources as Iran, such as Saudi Arabia, Egypt and Taiwan, have shown the same variations in the HER-2-positive breast cancer rate (El-A Helal et al, 2000;Kuo et al, 2007;Arafah., 2012). Taken together, we maintain that standardization is the first step toward improvement in IHC diagnosis by the HER-2 biomarker in breast cancer in Iran.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

Keyhani

Muhammadnejad²,

Karimlou³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment for HER-2/neu Status in Taiwanese Breast Cancer Patients

Abstract: The current algorithm to use HER-2 FISH as a supplementary role to IHC HercepTest 2+ may need some modifications according to the local setting. TOP2A FISH adds little value to HER-2 FISH and IHC staining in our study.

Cited by 18 publications

References 12 publications

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods

HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases

Prevalence of HER-2-Positive Invasive Breast Cancer: A Systematic Review from Iran

Contact Info

Product

Resources

About